Bristol Myers Squibb Company $BMY Stock Sold by North Dakota State Investment Board

Key Points

• North Dakota State Investment Board cut its Bristol Myers Squibb stake by 21.5% in the third quarter, selling 17,084 shares and retaining 62,548 shares valued at approximately $3.9 million.
• Analyst sentiment was mixed, with ratings ranging from underweight to buy; overall, BMY had a consensus “Hold” rating and an average price target of $65.50.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates, while revenue rose 5.7% year over year to $12.97 billion. The company also declared a quarterly dividend of $0.63 per share, representing a 4.2% annualized yield.

North Dakota State Investment Board lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 21.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,548 shares of the biopharmaceutical company's stock after selling 17,084 shares during the quarter. North Dakota State Investment Board's holdings in Bristol Myers Squibb were worth $3,903,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. North Star Investment Management Corp. raised its holdings in shares of Bristol Myers Squibb by 2.9% in the 3rd quarter. North Star Investment Management Corp. now owns 26,488 shares of the biopharmaceutical company's stock valued at $1,653,000 after buying an additional 747 shares during the period. Beacon Bank & Trust acquired a new position in Bristol Myers Squibb during the 3rd quarter worth about $221,000. Sigma Investment Counselors Inc. acquired a new position in Bristol Myers Squibb during the 3rd quarter worth about $213,000. William Mack & Associates Inc. acquired a new position in Bristol Myers Squibb during the 3rd quarter worth about $35,000. Finally, Victory Financial Group LLC purchased a new position in Bristol Myers Squibb during the 3rd quarter valued at about $228,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company's stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the subject of several research reports. Citigroup reaffirmed a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Morgan Stanley reiterated an "underweight" rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. Guggenheim reissued a "buy" rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Finally, Roth Capital started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $65.50.

Bristol Myers Squibb Stock Down 1.7%

Bristol Myers Squibb stock opened at $60.51 on Thursday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The stock's fifty day simple moving average is $62.98 and its 200-day simple moving average is $59.88. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $123.59 billion, a P/E ratio of 13.33, a P/E/G ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.46 earnings per share. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb's dividend payout ratio is 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: A Bristol Myers Squibb cancer drug reportedly doubled progression-free survival in a study and also showed encouraging results in other solid tumors. The data could strengthen the company’s growth portfolio and help offset concerns about future product declines. Bristol Myers Squibb Cancer Drug Trial Article
• Positive Sentiment: One valuation analysis argues that BMY still trades below its estimated fair value and highlights the company’s cash-generation potential. That view may attract value-oriented investors following the stock’s substantial one-year advance. Bristol Myers Squibb Fair Value Analysis
• Neutral Sentiment: Bristol Myers Squibb is scheduled to report third-quarter results before the market opens Thursday. Pre-earnings coverage is focused on revenue, earnings, full-year guidance and performance from key growth products, making the report the next major catalyst for BMY. Bristol Myers Squibb Q3 2026 Earnings Preview
• Neutral Sentiment: Analyst opinions remain divided. A consolidated fair-value estimate fell from $66.71 to $65.25, while individual targets range from the $50s to the $80s, reflecting differing expectations for pipeline data, potential corporate actions and future cash flows. Bristol Myers Squibb Fair Value and Analyst Views
• Negative Sentiment: Piper Sandler cut its price target for BMY, adding pressure to the shares ahead of earnings. The target reduction suggests more cautious expectations for near-term operating performance or the company’s pipeline. Piper Sandler Price Target Cut
• Negative Sentiment: Zacks Research made small cuts to its fiscal 2027 and 2028 EPS estimates and maintains a “Hold” rating. The lower forecasts reinforce concerns that earnings may decline beyond the current year, when analysts expect approximately $6.51 per share. Bristol Myers Squibb Analyst Estimates

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.